investigator at theNational Institutes of Health ( NIH)have set in motion aphase 1 clinical trialassessing the potential of a worldwide flu vaccinum nominee in humanity . call FluMos - v1 , the investigative nanoparticle influenza vaccine was develop to provide lasting protection against various dissimilar tune of flu ( the virus that causes the common flu ) .
The latest FluMos - v1 candidate has outperformedstandard flu vaccinesin pre - clinical animal study and exhibit hope as a nominee to move into human clinical trials .
Normally , received grippe vaccines ask to be reformulated on a yearly basis to detain up to engagement with emerging strains . The HA protein area of the virus is a rough-cut focus area , with vaccines being adapted to target this switch protein in influenza strains that are bode to become prevailing in the coming flu time of year . If the received influenza vaccine is not well - match to target the ever - change HA protein , it results in a reduction in antibody output for that given computer virus strain and reduces the overall resistant protection provided . Therefore , auniversal flu vaccinethat could elicit a hard and long-lived antibody response to a all-encompassing range of influenza strains has been highly sought after . In the latterly launched test , FluMos - v1 will point the HA proteins of 4 different strains of influenza .
“ The health and economic essence of flu are square , and the world severely require amend flu vaccine , ” saidNIAID DirectorAnthony Fauci in astatement . “ I am encouraged by the majuscule hope of the VRC nanoparticle vaccine candidate , which so far has performed very well in pre - clinical testing . ”
The run is have place at the NIH ’s Clinical Center in Bethesda , Maryland , and is officious recruiting sizable player between the ages of 18 and 50 . The study is attend to enroll a total of 40 participants , break into three radical . Group one will receive 20 - micrograms ( mcg ) of FluMos - v1 , while Group two will incur a received seasonal influenza vaccinum , representing the ascendancy grouping . If FluMos - v1 at the 20mcg dose is found to be well tolerated and safe , a third group will pick up 60mcg of the FluMos - v1 fact-finding vaccinum and the outcomes for all three radical will be liken .
All the participants will self - account using a journal the hebdomad follow their vaccination and report any adverse response or health concerns . They will also be taking a record of their temperature day by day and report the amount of swelling and rubor around the injection site .
The participants will then return after 40 weeks ( one full flu time of year ) to the NIH in Bethesda , Maryland , to have further tests done . Blood tests will be taken to depend for any retentive - term mental defectiveness . They will also evaluate the number of antibodies farm against the HA protein of the virus strains following the vaccination to see how well the investigative vaccine had worked . For those that obtain FluMos - v1 , samples of their oral mucosa will also be taken to tax the localize immune response to the vaccine .
The phase 1 trial has an estimated completion date of May 1 , 2023 , after which the event will unwrap whether the nominee FluMos - v1 could be travel into a larger phase 2 trial if safety and dose criteria are met .
